Drugs / BAT2206
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04371185 | Aug 2020 → Apr 2021 | psoriasis | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04728360 | Jul 2021 → Oct 2022 | psoriasis | Bio-Thera Solutions | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT2206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04728360 ↗ |
| Route | Subcutaneous | “single subcutaneous injection (45 mg) of either BAT2206 or ustekinumab” PMID 36417156 ↗ Nov 2022 |